What are your top takeaways in Gynecologic Cancers from ASCO 2022?

1. ATHENA (LBA5500)

- Consistent efficacy signal with PARPi maintenance therapy in the front line
- Another potential option for our patients with greater dosing flexibility
- The BICR PFS difference in the HRP population really caught my attention. Nearly a 6 month improvement with median PFS in the r...

ASCO 2022 for Gynecologic Oncology had many great presentations. Data from the following 3 trials are all likely practice-changing, particularly the ATHENA-MONO trial. This study reaffirms the pivotal role PARPis play in maintenance therapy after first-line platinum-based chemotherapy in ovarian can...